A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs REGN 2477 (Primary) ; Trevogrumab (Primary)
- Indications Muscular disorders
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 17 Nov 2017 Planned End Date changed from 22 Feb 2018 to 1 Nov 2018.
- 17 Nov 2017 Planned primary completion date changed from 22 Feb 2018 to 1 Nov 2018.
- 15 Nov 2017 Planned End Date changed from 5 Oct 2018 to 22 Feb 2018.